Abstract: The present disclosure provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A?42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A?42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.

Abstract: The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A?42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A?42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.

Abstract: The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of certain types of oligomers in a subject. More specifically, the drugs and compositions reduce or prevent the formation of oligomers formed from tau protein, TDP-43, Huntingtin's protein and/or alpha-synuclein. It further provides a method of reducing formation of or disrupting TDP-43, alpha-synuclein, Huntingtin's protein and/or tau protein oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.

Abstract: The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A?42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A?42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.